PEG in ADC Linker Design: The Solubilizing Spacer
In antibody-drug conjugate design, the linker connecting the antibody to the cytotoxic payload is far more than a passive tether. PEG segments incorporated into ADC linkers serve as hydrophilic spacers that counteract the inherent hydrophobicity of potent payloads such as auristatins, maytansinoids, and pyrrolobenzodiazepine (PBD) dimers. Without adequate PEG spacer length, hydrophobic payloads drive ADC aggregation, reduce conjugation efficiency, and accelerate plasma clearance -- all of which compromise therapeutic index.
Solubility Enhancement for Hydrophobic Payloads
Many ADC payloads are highly hydrophobic, with logP values exceeding 3-5. Incorporating PEG4 to PEG24 spacers between the cleavable dipeptide and the payload dramatically improves aqueous solubility of the drug-linker construct. This is critical for achieving homogeneous conjugation at higher drug-to-antibody ratios (DAR) without inducing aggregation. PEG spacers of 12-24 ethylene oxide units are commonly used in clinically validated ADC linkers to maintain conjugate solubility at DAR 4-8.
Spacer Between Antibody and Cleavable Linker
The PEG segment acts as a physical spacer between the bulky antibody (approximately 150 kDa) and the enzymatic cleavage site. Without sufficient spacing, the antibody's steric bulk can shield the cleavable motif from lysosomal proteases such as cathepsin B. PEG spacers of PEG4-PEG8 positioned N-terminal to the Val-Cit-PABC sequence ensure the enzyme can access the cleavage site, improving intracellular payload release efficiency by 2-5 fold compared to PEG-free linkers.
Reducing ADC Aggregate Formation
Hydrophobic payloads attached to antibodies increase the tendency for inter-molecular hydrophobic interactions that drive aggregation during conjugation, purification, and storage. PEG spacers create a hydration shell around the drug-linker construct, reducing the effective hydrophobicity of the conjugate and enabling DAR 8 ADCs to maintain greater than 95% monomer content. This aggregation suppression is particularly important for cysteine-conjugated ADCs, where partial reduction exposes hydrophobic interchain regions.
Linker Length and Payload Accessibility
PEG linker length directly influences intracellular trafficking and payload release. Shorter PEG2-PEG4 linkers provide compact conjugates with rapid lysosomal processing but may limit enzyme access. Longer PEG8-PEG24 spacers improve cathepsin B accessibility and enable efficient bystander killing, where released payload diffuses to neighboring antigen-negative tumor cells. However, excessively long PEG linkers (greater than PEG36) can reduce conjugation efficiency and increase manufacturing complexity without additional therapeutic benefit.
PEG in Peptide-Drug Conjugate (PDC) Linkers
Peptide-drug conjugates leverage short targeting peptides (typically 5-30 amino acids) to deliver cytotoxic payloads to tumor cells expressing specific receptors. Compared to ADCs, PDCs face a different set of design challenges: the targeting peptide is orders of magnitude smaller than an antibody, meaning the payload-linker construct contributes proportionally more to the overall physicochemical properties of the conjugate. PEG linkers in PDCs serve to balance the hydrophobicity of the payload while preserving peptide receptor-binding affinity.
Hydrophilicity Compensation for Small Targeting Peptides
Short targeting peptides often contain hydrophobic residues essential for receptor binding. When conjugated to equally hydrophobic cytotoxic payloads, the resulting PDC can exhibit poor aqueous solubility and rapid aggregation. PEG4-PEG12 spacers inserted between the peptide C-terminus and the cleavable linker provide sufficient hydrophilicity to maintain conjugate solubility without disrupting the peptide's binding conformation. This is especially critical for cyclic peptide-based PDCs targeting integrins or somatostatin receptors.
Linker Design Differences from ADCs
Unlike ADCs where the antibody provides 70-90% of the conjugate mass, PDC linkers contribute a substantial fraction of the total molecular weight. PEG spacers in PDCs must therefore be carefully optimized: excessive PEG length can dominate hydrodynamic radius and alter receptor-binding kinetics, while insufficient PEG length fails to solubilize the payload. PEG6-PEG12 represents the typical sweet spot for PDC applications, balancing the payload solubility gains against the risk of sterically obstructing peptide-receptor interactions.
Enzymatic Stability in Circulation
PDCs are more susceptible to systemic proteolysis than ADCs due to the exposed peptide backbone. PEG spacers positioned adjacent to the peptide can shield protease cleavage sites through steric hindrance and hydration layer effects. This strategy has been employed in clinically investigated PDCs targeting prostate-specific membrane antigen (PSMA) and bombesin receptors, where PEG4-PEG8 spacers extended plasma half-life from minutes to hours by reducing non-specific proteolytic degradation.
Tumor-Selective Cleavage with PEG Linkers
PDCs benefit from the same enzyme-cleavable PEG linker strategies validated in ADCs. Cathepsin B-sensitive Val-Cit-PABC sequences connected through PEG spacers release payload selectively in the lysosomal compartment of target cells. The PEG segment ensures that the bulky peptide-payload construct is efficiently processed by lysosomal enzymes. Additionally, PEG linkers reduce non-specific payload release in plasma by shielding the cleavage site from circulating esterases and proteases.
Comparison of PEG Linker Roles Across Drug Conjugate Modalities
The function, optimal molecular weight, and design priorities of PEG linkers vary substantially across conjugate types. The table below provides a systematic comparison of PEG linker applications in ADCs, PDCs, PROTACs, and small-molecule conjugates.
| Conjugate Type | Primary PEG Role | Typical PEG MW / Units | Preferred Chemistry | Key Design Challenge |
|---|---|---|---|---|
| ADC (Antibody-Drug Conjugate) | Solubilize hydrophobic payload; space cleavable linker from antibody; reduce aggregation at DAR 4-8 | PEG4-PEG24 (176-1056 Da) | Maleimide-thiol or NHS-amine conjugation to antibody; Val-Cit-PABC-PEG-payload assembly | Balancing PEG length against DAR homogeneity and cathepsin B accessibility |
| PDC (Peptide-Drug Conjugate) | Compensate for small peptide hydrophobicity; protect peptide from proteolysis; maintain receptor binding | PEG4-PEG12 (176-528 Da) | Solid-phase peptide synthesis with PEG-amino acid building blocks; C-terminal payload attachment | Preventing PEG-induced steric hindrance of peptide-receptor interaction |
| PROTAC (Proteolysis-Targeting Chimera) | Improve aqueous solubility and cell permeability; optimize ternary complex geometry | PEG1-PEG8 (44-352 Da) | Amide or ether linkage connecting POI ligand to E3 ligase ligand; modular click assembly | Tuning linker length and composition to avoid unproductive ternary complexes |
| Small-Molecule Conjugate | Enhance solubility of lipophilic drugs; enable prodrug release; reduce non-specific protein binding | PEG2-PEG12 (88-528 Da) | Ester, carbonate, or hydrazone-linked PEG for pH or enzyme-triggered release | Achieving predictable release kinetics without compromising conjugate stability |
| Click-Chemistry ADC | Site-specific conjugation spacer; improve bioorthogonal reaction efficiency | PEG4-PEG12 (176-528 Da) | Azide-PEG or DBCO-PEG for strain-promoted or copper-catalyzed click conjugation | Minimizing PEG-related immune recognition while maintaining conjugation yield |
PEG in PROTAC Linker Design: Solubility, Permeability, and Ternary Complex Optimization
PROTAC molecules present a unique linker design challenge: the linker must simultaneously provide sufficient length to span the distance between the E3 ligase and the target protein within a productive ternary complex, while maintaining adequate drug-like properties including solubility, permeability, and metabolic stability. PEG-based linkers have emerged as a dominant scaffold in PROTAC design due to their conformational flexibility, tunable hydrophilicity, and well-established synthetic accessibility.
Improving PROTAC Solubility
PROTACs frequently violate Lipinski's Rule of Five due to their high molecular weight (700-1100 Da) and the combined hydrophobicity of two protein-binding ligands. PEG2-PEG8 linkers introduce polar ethylene oxide units that dramatically improve aqueous solubility without adding excessive molecular weight. PROTACs with PEG linkers typically show 5-10 fold higher aqueous solubility compared to alkyl-linked analogs, enabling higher concentrations in cellular assays and improving oral bioavailability potential. PEG linkers of 3-6 units represent the most commonly used range in published PROTACs, as they provide sufficient solubility enhancement while maintaining reasonable permeability.
Permeability Modulation
PEG linkers create a paradox in PROTAC design: they improve solubility but can reduce passive membrane permeability due to increased polar surface area and hydrogen bond donors. PROTACs with PEG4-PEG6 linkers maintain adequate permeability when the total number of hydrogen bond donors is kept below 5. Strategic placement of the PEG linker -- flanked by more lipophilic segments that facilitate membrane partitioning -- can achieve a productive balance. Some PROTAC designs alternate PEG units with alkyl or rigid aromatic segments to fine-tune this solubility-permeability trade-off.
Linker Length and Ternary Complex Geometry
The PEG linker length directly controls the spatial relationship between the target protein and E3 ligase within the ternary complex. Linkers that are too short (PEG1-PEG2) prevent simultaneous binding of both protein partners, while excessively long linkers (greater than PEG12) increase the entropic penalty of ternary complex formation and can promote unproductive binary complexes. Systematic PEG linker length scanning -- synthesizing a series of PROTACs with PEG1 through PEG8 -- is standard practice during PROTAC optimization and typically identifies a 2-3 unit window of maximal degradation efficiency.
PEG vs Alkyl vs Rigid Linkers in PROTACs
Comparative studies of linker composition in PROTACs have demonstrated that PEG linkers generally outperform purely alkyl linkers of equivalent length in cellular degradation assays. The conformational flexibility of PEG allows the ternary complex to sample productive geometries, while the oxygen atoms can engage in transient hydrogen bonds that stabilize the protein-protein interface. However, rigid linkers incorporating piperazine or aryl rings can provide advantages when a fixed geometry is required to avoid steric clashes between the ligase and target protein. PEG-alkyl hybrid linkers combine the solubility of PEG segments with the reduced rotatable bond count of alkyl chains.
Cleavable vs Non-Cleavable PEG Linkers in ADC Context
The decision between cleavable and non-cleavable PEG linkers fundamentally shapes ADC pharmacology. Cleavable PEG linkers exploit the unique intracellular environment of cancer cells -- lysosomal proteases, acidic pH, and reductive glutathione -- to release free payload, while non-cleavable linkers rely on complete antibody catabolism to liberate the active species. This section examines the design principles, enzyme selectivity, and release kinetics of cleavable PEG linker systems, with particular focus on the cathepsin B-cleavable Val-Cit-PABC-PEG architecture that has been validated in multiple approved ADCs.
Cathepsin B-Cleavable Mechanism
Cathepsin B is a cysteine protease overexpressed in the lysosomes of many tumor types and largely inactive in the extracellular environment due to pH and redox conditions. The Val-Cit (valine-citrulline) dipeptide is specifically recognized and cleaved by cathepsin B at the C-terminal amide bond of citrulline. When incorporated into PEG-containing linkers as Val-Cit-PABC-PEG-payload, this sequence provides tumor-selective payload release with high plasma stability (less than 2% payload release over 7 days in human plasma). The PEG spacer N-terminal to the Val-Cit motif ensures the enzyme can physically access the cleavage site, while the PABC (p-aminobenzyloxycarbonyl) self-immolative spacer C-terminal to the dipeptide enables traceless payload release.
Val-Cit-PABC-PEG Linker Architecture
The Val-Cit-PABC-PEG linker represents the most clinically validated cleavable ADC linker design. The architecture proceeds from antibody attachment through a thiol-maleimide or amide bond, followed by a PEG spacer (PEG4-PEG8), the cathepsin B-cleavable Val-Cit dipeptide, the PABC self-immolative group, and finally the cytotoxic payload attached via a carbamate bond. Upon internalization and lysosomal trafficking, cathepsin B cleaves the Cit-PABC amide bond, triggering 1,6-elimination of the PABC group and release of the free payload with carbon dioxide and 4-aminobenzyl alcohol as benign byproducts. This design has been employed in clinical-stage and approved ADCs.
Non-Cleavable PEG Linker Strategies
Non-cleavable PEG linkers, typically maleimide-PEG4-PEG8 attached via thiol to interchain cysteines, rely on complete lysosomal degradation of the antibody to release the active payload species. The released catabolite retains the linker attachment (e.g., payload-linker-lysine or payload-linker-cysteine adduct), which can affect the cytotoxic mechanism and the bystander killing effect. Non-cleavable linkers offer superior plasma stability -- essentially zero premature payload release -- and are preferred when the payload-linker-lysine catabolite retains potent activity. This approach is exemplified by trastuzumab emtansine (Kadcyla), though that particular ADC uses a non-PEG SMCC linker.
Cleavable PEG Linker Design Principles
Effective cleavable PEG linkers must satisfy three criteria: (1) the PEG spacer must provide sufficient distance between the antibody surface and the enzyme recognition site to avoid steric occlusion; (2) the cleavage site must be completely stable in circulation (pH 7.4, 37 degrees C) but rapidly processed upon internalization; and (3) the released payload must be the unmodified cytotoxic species. PEG4-PEG8 spacers positioned between the antibody attachment point and the Val-Cit motif satisfy the first criterion. The Val-Cit dipeptide's selectivity for cathepsin B over circulating proteases satisfies the second. The PABC self-immolative group satisfies the third by releasing payload without residual linker fragments.
Enzyme Selectivity and Bystander Effect
Cathepsin B-cleavable PEG linkers enable the bystander killing effect, where released hydrophobic payload diffuses from antigen-positive target cells into neighboring antigen-negative tumor cells. The PEG linker composition influences bystander efficiency: shorter PEG spacers (PEG2-PEG4) produce faster intracellular cleavage but may release payload species with residual polar linker fragments that limit membrane permeability. Longer PEG spacers (PEG8-PEG12) can slow cleavage kinetics but release free payload with higher membrane permeability, enhancing bystander killing. The optimal balance depends on tumor antigen heterogeneity in the specific indication.
Release Kinetics: Cleavable vs Non-Cleavable
Cathepsin B-cleavable PEG linkers release payload with a half-life of 2-6 hours in the lysosomal compartment after ADC internalization, producing free payload that can engage both intracellular targets and, through bystander diffusion, neighboring cells. Non-cleavable linkers release their active catabolite only upon complete antibody proteolysis, a slower process (12-48 hours) that produces a charged linker-amino acid-payload species with more limited membrane permeability. The choice between these mechanisms depends on whether the clinical strategy prioritizes systemic stability (non-cleavable) or bystander-mediated tumor eradication in heterogeneous antigen expression (cleavable).
PEG Molecular Weight Effects on ADC DAR and Aggregation
The molecular weight and length of PEG spacers in ADC drug-linker constructs directly influence two critical quality attributes: drug-to-antibody ratio (DAR) homogeneity and conjugate aggregation propensity. As ADC developers push toward higher DAR values (DAR 6-8) to increase potency, the role of PEG in managing the physicochemical consequences becomes increasingly important. Understanding the relationship between PEG chain length, DAR, and aggregation behavior is essential for rational ADC linker design.
DAR Control Through PEG Linker Design
PEG linker design affects achievable DAR through both steric and solubility mechanisms. Longer PEG spacers (PEG8-PEG24) increase the hydrodynamic radius of each drug-linker construct, creating steric crowding at the antibody surface that restricts the number of payloads that can be attached through cysteine conjugation. This steric limitation can be exploited to narrow the DAR distribution: PEG12-PEG24 drug-linkers conjugated to partially reduced interchain cysteines produce predominantly DAR 4 rather than DAR 8 species, improving batch-to-batch consistency and simplifying analytical characterization.
Aggregation Prevention at High DAR
Each additional hydrophobic payload attached to an antibody increases the conjugate's overall hydrophobicity and aggregation tendency. ADC aggregation typically becomes measurable at DAR 4-6 and can exceed 20-30% aggregate content at DAR 8 without adequate PEG solubilization. PEG12-PEG24 spacers reduce aggregate formation at DAR 8 to less than 5% by creating a hydrophilic corona around each payload attachment site. The PEG chain forms a hydration shell that shields the hydrophobic payload from intermolecular contact, functioning as a molecular-scale solubilizing excipient distributed across the antibody surface.
PEG MW-DAR Correlation Across Payload Classes
The required PEG spacer length scales with payload hydrophobicity. Moderately hydrophobic auristatins (MMAE, MMAF) typically require PEG4-PEG8 to achieve DAR 4 with less than 2% aggregate. Highly hydrophobic maytansinoids (DM1, DM4) benefit from PEG8-PEG12 spacers at the same DAR. PBD dimers, among the most hydrophobic ADC payloads (clogP greater than 4), frequently require PEG12-PEG24 spacers to maintain less than 5% aggregate at DAR 2-4. This empirical correlation allows early-stage linker design decisions based on payload physicochemical properties rather than trial-and-error screening.
Hydrophobic Payload Compatibility Screening
Systematic compatibility screening of PEG spacer lengths against payload hydrophobicity can accelerate ADC linker optimization. A typical screening workflow synthesizes drug-linker constructs with PEG2, PEG4, PEG8, PEG12, and PEG24 spacers, conjugates each to a model antibody at DAR 4 and DAR 8, and assesses percent aggregate by analytical SEC-HPLC. Hydrophobic interaction chromatography (HIC) provides additional resolution of DAR species. Payloads requiring PEG24 to maintain less than 5% aggregate at DAR 4 may be unsuitable for clinical development regardless of in vitro potency, making this screening an important early gating step in payload selection.
Self-Immolative Spacers and Click Chemistry PEG for Site-Specific Conjugation
Two advanced linker technologies -- self-immolative spacers and click chemistry PEG -- address complementary challenges in drug conjugate design. Self-immolative spacers enable traceless payload release after enzymatic or chemical trigger activation, while click chemistry PEG facilitates site-specific, stoichiometrically controlled conjugation that produces homogeneous ADC products with precisely defined DAR and attachment sites.
Self-Immolative Spacer Mechanism
Self-immolative spacers are chemical modules that undergo spontaneous fragmentation upon a specific trigger event, releasing the payload without residual linker fragments. The PABC (p-aminobenzyloxycarbonyl) spacer, the most widely used self-immolative group in ADC linkers, undergoes 1,6-elimination after enzymatic cleavage of the preceding motif. When integrated into Val-Cit-PABC-PEG-payload constructs, the PABC group serves as both a spacer and a release module. After cathepsin B cleavage of the Cit-PABC amide bond, the resulting aniline nitrogen electron pair triggers elimination, releasing the payload, CO2, and 4-aminobenzyl alcohol.
PEG-Spacer Integration in Self-Immolative Design
The integration of PEG segments with self-immolative spacers can follow two architectures: PEG positioned N-terminal to the self-immolative group (trigger-PEG-spacer-payload) improves enzyme accessibility, while PEG positioned C-terminal (trigger-spacer-PEG-payload) provides solubility close to the payload. The N-terminal PEG architecture (Val-Cit-PABC-PEG4-payload) has shown improved cathepsin B processing compared to the C-terminal architecture, likely because the PEG segment creates space between the enzyme recognition site and the bulky antibody. Some linker designs incorporate PEG segments on both sides of the cleavage motif for maximal solubility and enzyme access.
Click Chemistry for Site-Specific ADC Conjugation
Click chemistry approaches, particularly strain-promoted azide-alkyne cycloaddition (SPAAC) and copper-catalyzed azide-alkyne cycloaddition (CuAAC), enable site-specific ADC conjugation by incorporating azide-PEG or DBCO-PEG functional groups into the drug-linker construct. Unnatural amino acids bearing azide or alkyne groups are incorporated at defined positions in the antibody sequence, providing unique bioorthogonal handles. The PEG spacer length between the click-reactive group and the payload (typically PEG4-PEG12) controls conjugation efficiency by modulating steric accessibility of the bioorthogonal handle on the folded antibody surface.
Strain-Promoted and Copper-Free Approaches
Strain-promoted azide-alkyne cycloaddition (SPAAC) using DBCO-PEG-payload constructs has gained prominence for site-specific ADC manufacturing because it eliminates the copper catalyst that can oxidize sensitive protein residues. DBCO-PEG4-PEG8-payload reagents react with azide-modified antibodies within 2-4 hours at room temperature, achieving greater than 95% conjugation efficiency at stoichiometric ratios. The PEG spacer serves the dual purpose of improving DBCO reagent solubility and providing the physical spacing necessary for the strained cyclooctyne to access buried or partially shielded azide groups on the antibody surface.
PEGylated vs Non-PEGylated Drug Conjugates: Comparative Analysis
The inclusion of PEG spacers in drug conjugate linkers represents a deliberate design choice with measurable impacts on conjugate physicochemical properties, manufacturing, pharmacology, and safety. The table below summarizes key differences between PEGylated and non-PEGylated drug conjugate designs across multiple evaluation criteria.
| Parameter | PEGylated Conjugate | Non-PEGylated Conjugate |
|---|---|---|
| Aqueous Solubility | High: PEG hydration shell solubilizes hydrophobic payloads, enabling conjugation at higher concentrations (5-10 mg/mL) with minimal precipitation | Variable: Hydrophobic payloads may limit conjugation concentration to less than 2 mg/mL; organic co-solvents (DMSO, DMF at 5-15%) frequently required |
| ADC Aggregation at DAR 8 | Less than 5% aggregate with PEG12-PEG24 spacers; hydrophilic corona prevents intermolecular hydrophobic interactions | 15-40% aggregate; hydrophobic payloads promote intermolecular association and precipitation during conjugation and storage |
| DAR Homogeneity | PEG steric bulk narrows DAR distribution in random cysteine conjugation; site-specific click approaches achieve DAR 2 or DAR 4 with greater than 95% homogeneity | Broader DAR distribution (0-8 species) in random cysteine conjugation; requires extensive chromatographic purification to isolate desired DAR species |
| Cathepsin B Cleavage Efficiency | PEG4-PEG8 spacers improve enzyme access to Val-Cit motif by 2-5 fold compared to PEG-free designs; faster intracellular payload release kinetics | Antibody steric bulk partially shields cleavage site; slower and potentially incomplete lysosomal processing of the linker-payload construct |
| Plasma Stability | Comparable to non-PEGylated when PEG segment does not alter the protease recognition site; PEG hydration shell may provide modest additional protection | High when proper cleavable motifs (Val-Cit, Val-Ala) are used; stability determined primarily by the protease recognition sequence, not linker hydrophilicity |
| Immunogenicity Risk | Low but measurable: PEG can elicit anti-PEG antibodies with repeated dosing, potentially accelerating clearance of subsequent doses (ABC phenomenon) | Minimal: No PEG-related immunogenicity; immune responses directed only against the antibody or payload components of the conjugate |
| Manufacturing Complexity | Moderate: PEG reagent synthesis, purification, and characterization add steps; PEG polydispersity contributes to product-related impurity profile | Lower: Fewer synthetic steps; simpler impurity profiles; established manufacturing platforms for non-PEGylated linker-payload constructs |
How Can BOC Sciences Support PEG Linker Development for Drug Conjugates?
BOC Sciences provides comprehensive PEG linker reagents, custom linker synthesis, PEG derivative manufacturing, and drug conjugate support services to facilitate linker design, optimization, and scale-up across ADC, PDC, PROTAC, and small-molecule conjugate programs.
ADC Linker-Payload PEG Reagents
PEG linkers optimized for antibody-drug conjugate assembly with defined purity and functionality.
- Maleimide-PEGn-NHS and Maleimide-PEGn-azide heterobifunctional PEG
- Val-Cit-PABC-PEGn-payload drug-linker constructs
- PEG4-PEG24 spacers for MMAE, DM1, and PBD payload compatibility
- Certificates with NMR, HPLC, and MALDI-TOF characterization
Cleavable PEG Linker Synthesis
Custom cleavable PEG linkers with defined release triggers for conjugate-specific release profiles.
- Cathepsin B-cleavable Val-Cit-PABC-PEG and Val-Ala-PABC-PEG
- pH-sensitive hydrazone-PEG and acetal-PEG linkers
- Reducible disulfide-PEG and glutathione-sensitive linkers
- Custom cleavage motif integration per project requirements
PROTAC PEG Linkers
PEG linker building blocks and modular PROTAC assembly reagents for targeted protein degradation.
- PEG1-PEG8 linkers with amine, carboxylic acid, or azide termini
- PEG-alkyl and PEG-aryl hybrid linker scaffolds
- Cereblon and VHL ligand-PEG-linker intermediates
- Monodisperse PEG for crystallography-grade PROTAC synthesis
Click Chemistry PEG Reagents
Bioorthogonal PEG reagents for site-specific drug conjugation through click chemistry approaches.
- Azide-PEGn-amine, DBCO-PEGn-NHS for SPAAC conjugation
- Alkyne-PEGn-azide for CuAAC click assembly
- Tetrazine-PEGn and TCO-PEGn for inverse electron-demand Diels-Alder
- BCN-PEGn derivatives for metal-free strain-promoted conjugation
Monodisperse and Low-Dispersity PEG
Single-molecular-weight PEG linkers for homogeneous drug conjugates with simplified characterization.
- Defined PEGn oligomers (n = 2, 4, 6, 8, 12, 24) with single-peak HPLC
- Monodisperse heterobifunctional PEG for precise linker stoichiometry
- Low-PDI polydisperse PEG (PDI less than 1.03) for cost-sensitive applications
- Custom PEG chain length synthesis on request
Custom PEG Linker Design and Scale-Up
Collaborative linker design and process development from milligram screening to multi-gram production.
- De novo PEG linker design for novel conjugate programs
- Scale-up from mg to kg with batch reservation
- Process impurity profiling and reference standard preparation
- Regulatory starting material documentation support
Discuss PEG Linker Requirements for Your Drug Conjugate Program
Share your conjugate modality (ADC, PDC, PROTAC, or small-molecule), payload class, desired PEG spacer length, and linker chemistry (cleavable, non-cleavable, or click-based). BOC Sciences can recommend suitable PEG reagents or develop customized linker solutions for your specific conjugate design.
Explore Related PEG Drug Delivery and Conjugate Design Guides
Continue exploring PEG linkers, drug conjugate design, and related topics across the drug delivery landscape.
Frequently Asked Questions
Quick answers to common questions about PEG linkers in drug conjugate design.
Why are PEG linkers necessary in ADC design?
What is the difference between cleavable and non-cleavable PEG linkers in ADCs?
How does PEG molecular weight affect ADC aggregation and DAR?
What role does PEG play in PROTAC linker design?
How can BOC Sciences support PEG linker development for drug conjugates?
Request PEG Linker Support or Custom Conjugate Solutions
Share your drug conjugate program details: conjugate modality (ADC, PDC, PROTAC, or small-molecule), payload class, desired PEG spacer length and chemistry, and specific linker requirements. BOC Sciences can recommend suitable PEG reagents or develop customized linker solutions for your conjugate development needs.
